Should You Hold Ambarella Inc (AMBA), 3D Systems Corporation (DDD) And Juno Therapeutics Inc (JUNO)?

Posted by Kristi Scott December 29, 2014 0 Comment 1547 views

New York, NY – GDP INSIDER  – 12/29/2014.

Expectations seem to be gaining on the shares of Ambarella Inc (NASDAQ:AMBA), 3D Systems Corporation (NYSE:DDD) and Juno Therapeutics Inc (NASDAQ:JUNO). All the three stocks witnessed upbeat sentiments from investors’. Juno made its debut on Friday with a big bang.

The chipmaker has been getting good support from investors. Ambarella Inc (NASDAQ:AMBA) Chips were used in digital cameras, which included sports action cameras manufactured by GoPro Inc (NASDAQ:GPRO). Its shares broke out 50-day line for the second time since early September. Shares closed 17% more than the 50-day moving average price, which was a key support level.

Will AMBA Continue To Move Higher Or Are Things About To Reverse? See What Is Next For AMBA With A Free Trend Analysis

Its shares were gaining ground since analysts’ expect the company to report bumper earnings per share. They estimate 88% earnings per share growth in the next quarter on top of 84% EPS growth achieved in the most recent quarter.

Analysts’ from different brokerage houses seem to be bullish on the stock of 3D Systems Corporation (NYSE:DDD). However, Longbow differed from others as the brokerage initiated coverage with a rating of Underperform and kept the price tag of $25.

Could DDD Reverse From Here Or Will Momentum Continue? Get A Hint As To What’s Coming Next With A Free Trend Analysis Report

Three brokerages, Citigroup Inc (NYSE:C), Imperial Capital and Oppenheimer have a 12-month price objective of $40, $42 and $57 respectively. While Citigroup has a rating of Neutral, the other two brokerages have a rating of Outperform on 3D Systems shares.

Shares of the company gained despite Google Inc (NASDAQ:GOOGL)’s recent comment that it would not be using 3D-printed materials for its Project Ara.

The company closed its IPO only recently. Juno Therapeutics Inc (NASDAQ:JUNO) made a strong impact on the first day of its listing of shares. It was one of the few companies to record significant upside on debut.

Will JUNO Continue To Trend Higher Or Are Things About To Crash? See What’s Coming Up Next For JUNO With A Complimentary Trend Analysis Report

Juno Therapeutics came out with an IPO of 12.7 million shares at a price of $24 per share. It included 1.7 million shares kept aside for underwriters. According to Renaissance Capital, about 100 IPOs were priced in the healthcare sector in 2014, which twice that of the last year.

Obviously, the success of the IPOs made three more companies to line up with their IPOs, which might hit the market next year.

About UltimateStockAlerts provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.

UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure:  UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

About Kristi Scott

Kristi Scott joined GDP Insider in 2005 as a Wall Street reporter for the Business and Market section. Kristi covers the stock market, financial markets and personal finance. Her awards have come from the National Federation of Professional Writers, the Ohio Newspaper Association, the Cleveland Press Club, the Society of Professional Journalists and Suburban Newspapers of America. Kristi was named SNA's national Journalist of the Year

View all post by Kristi Scott Visit author's website

Write Your Comment